{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:18:07Z","timestamp":1787771887277,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.urolonc.2018.10.016","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T01:44:11Z","timestamp":1542159851000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Kang-bo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-0177","authenticated-orcid":false,"given":"Ran-yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-hua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zai-shang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-juan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-8775","authenticated-orcid":false,"given":"Sheng-jie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang-hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang-zhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-ke","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-3033","authenticated-orcid":false,"given":"Zhuo-wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2018.10.016_bib0001","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0002","doi-asserted-by":"crossref","first-page":"E661","DOI":"10.1111\/j.1464-410X.2012.11453.x","article-title":"Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis","volume":"110","author":"Di Lorenzo","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0003","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bju.12450","article-title":"Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis","volume":"113","author":"Carthon","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0004","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clgc.2015.08.001","article-title":"Panitumumab treatment for advanced penile squamous cell carcinoma when surgery and chemotherapy have failed","volume":"14","author":"Necchi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0006","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yexmp.2015.11.024","article-title":"Comparative evaluation of the GP5+\/6+, MY09\/11 and PGMY09\/11 primer sets for HPV detection by PCR in oral squamous cell carcinomas","volume":"100","author":"Erhart","year":"2016","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0007","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41419-018-0736-1","article-title":"Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines","volume":"9","author":"Zhou","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40880-017-0180-0","article-title":"The loss-of-function mutations and down-regulated expression of ASB3 gene promote the growth and metastasis of colorectal cancer cells","volume":"36","author":"Du","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0009","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ijc.21009","article-title":"Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease","volume":"116","author":"Daling","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.juro.2014.02.2563","article-title":"Salvage surgical resection for isolated locally recurrent inguinal lymph node metastasis of penile cancer: international study collaboration","volume":"192","author":"Baumgarten","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0011","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/sti.2009.036061","article-title":"Referrals into a dedicated British penile cancer centre and sources of possible delay","volume":"85","author":"Lucky","year":"2009","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0012","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU guidelines on penile cancer: 2014 update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0013","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ucl.2016.06.009","article-title":"Emerging systemic therapies for the management of penile cancer","volume":"43","author":"Gupta","year":"2016","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0014","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.eururo.2011.08.028","article-title":"Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study","volume":"60","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0015","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.ejca.2010.03.036","article-title":"Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab","volume":"46","author":"Tol","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0016","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bju.14013","article-title":"First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study","volume":"121","author":"Necchi","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0017","doi-asserted-by":"crossref","first-page":"e62175","DOI":"10.1371\/journal.pone.0062175","article-title":"Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma","volume":"8","author":"Gou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0018","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry","volume":"23","author":"Chung","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0019","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature14969","article-title":"The genomic landscape of response to EGFR blockade in colorectal cancer","volume":"526","author":"Bertotti","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0020","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","article-title":"Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution","volume":"4","author":"Misale","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0021","doi-asserted-by":"crossref","first-page":"15617","DOI":"10.1038\/ncomms15617","article-title":"Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance","volume":"8","author":"Ali","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0022","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","article-title":"Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy","volume":"75","author":"McDaniel","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0023","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.humpath.2013.07.012","article-title":"The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases","volume":"44","author":"Chaux","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0024","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1634\/theoncologist.2016-0148","article-title":"Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer","volume":"21","author":"Rankin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0025","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0026","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","article-title":"Role of human papillomavirus in penile carcinomas worldwide","volume":"69","author":"Alemany","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0027","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1200\/JCO.2007.12.3182","article-title":"Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma","volume":"25","author":"Heideman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0028","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.juro.2014.08.087","article-title":"Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome","volume":"193","author":"Djajadiningrat","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0029","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.bcp.2010.07.013","article-title":"Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment","volume":"80","author":"Kim","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.urolonc.2018.10.016_bib0030","first-page":"3988","article-title":"Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma","volume":"7","author":"Almadori","year":"2001","journal-title":"Clin Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918304009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918304009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:14:22Z","timestamp":1761041662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143918304009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1078143918304009"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}